PLEURAL BIOPSY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Pleural Biopsy Market is estimated to be valued at USD 330.4 Mn in 2025 and is expected to reach USD 503.4 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032. The global pleural biopsy market represents a critical segment within the diagnostic healthcare landscape, encompassing procedures and technologies designed to extract tissue samples from the pleura for pathological examination. Pleural biopsy procedures serve as essential diagnostic tools for identifying various pleural conditions, including malignant pleural mesothelioma, lung cancer metastases, tuberculosis, and other inflammatory or infectious pleural diseases. The market encompasses multiple procedural approaches, including closed pleural biopsy using Abrams or Cope needles, thoracoscopic procedures, and CT-guided percutaneous biopsies, each offering distinct advantages in terms of diagnostic accuracy and patient safety.

The increasing prevalence of respiratory diseases, coupled with rising environmental exposure to carcinogenic substances and growing awareness of early disease detection, has significantly propelled market growth. Healthcare systems worldwide are witnessing substantial investments in advanced diagnostic technologies, with pleural biopsy procedures becoming increasingly sophisticated through integration of imaging guidance systems and minimally invasive techniques. The market's evolution is further driven by technological advancements in biopsy instruments, improved procedural safety protocols, and enhanced diagnostic accuracy, making pleural biopsy an indispensable component of modern pulmonary and thoracic medicine practices globally.

Market Dynamics

The global pleural biopsy market is experiencing robust growth, driven by multiple interconnected factors. The increasing incidence of lung cancer and mesothelioma serves as a primary growth catalyst, particularly as environmental and occupational exposures to asbestos and other carcinogenic substances continue to manifest in aging populations worldwide. Advanced technological innovations, including the development of sophisticated imaging-guided biopsy systems, minimally invasive thoracoscopic techniques, and enhanced needle biopsy instruments with improved precision and safety profiles, significantly drive market expansion by enabling more accurate diagnoses with reduced procedural complications.

The growing emphasis on early disease detection and personalized medicine approaches further accelerates market growth, as healthcare providers increasingly recognize the critical importance of obtaining high-quality tissue samples for molecular diagnostics and targeted therapy selection. The global pleural biopsy market is experiencing robust growth, driven by multiple interconnected factors. A key growth catalyst is the rising incidence of lung cancer and mesothelioma, especially as environmental and occupational exposures to asbestos and other carcinogenic substances continue to affect aging populations worldwide.

Regulatory challenges and lengthy approval processes for new biopsy devices also impede market growth. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in emerging economies, increasing healthcare expenditure, growing medical tourism, and the development of next-generation biopsy technologies incorporating artificial intelligence and robotic assistance, which promise to enhance procedural accuracy, reduce complications, and expand the accessibility of pleural biopsy procedures to broader patient populations globally.

Key Features of the Study

• This report provides in-depth analysis of the global pleural biopsy market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pleural biopsy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Olympus Corporation, Boston Scientific Corporation, Cook Medical, CONMED Corporation, Medtronic plc, B. Braun Melsungen AG, Hologic Inc., BD (Becton, Dickinson and Company), FUJIFILM Holdings Corporation, KARL STORZ SE & Co. KG, Ethicon (Johnson & Johnson), Argon Medical Devices, Richard Wolf GmbH, and Smiths Medical
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pleural biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleural biopsy market

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Biopsy Needles and Instruments
  • Thoracoscopes and Accessories
  • Imaging and Guidance Systems
  • Ancillary Equipment (suction devices, forceps, kits, etc.)
• Technique Insights (Revenue, USD Mn, 2020 - 2032)
  • Needle Biopsy (Closed Needle/Abrams Needle)
  • Thoracoscopic Pleural Biopsy (Medical Thoracoscopy/VATS)
  • Open Surgical Pleural Biopsy
• Diagnostic Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Malignant Pleural Effusion and Pleural Malignancies (e.g., mesothelioma, metastatic cancers)
  • Infectious Pleural Diseases (e.g., tuberculosis, bacterial/fungal pleuritis)
  • Inflammatory and Autoimmune Conditions (e.g., rheumatoid pleuritis, lupus)
  • Other Idiopathic or Unexplained Pleural Effusions
• Guidance Method Insights (Revenue, USD Mn, 2020 - 2032)
  • Image-Guided (CT-guided, Ultrasound-guided)
  • Non-Guided
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Olympus Corporation
  • Boston Scientific Corporation
  • Cook Medical
  • CONMED Corporation
  • Medtronic plc
  • Braun Melsungen AG
  • Hologic Inc.
  • BD (Becton, Dickinson and Company)
  • FUJIFILM Holdings Corporation
  • KARL STORZ SE & Co. KG
  • Ethicon (Johnson & Johnson)
  • Argon Medical Devices
  • Richard Wolf GmbH
  • Smiths Medical